title: Adenine/cytosine(1166) polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors.
abstract: BACKGROUND
  Most of the known actions of angiotensin II are mediated by the angiotensin II type 1 receptor (AGT1R). The adenine/cytosine(1166) (A/C(1166)) polymorphism of the AGT1R gene has been shown to be associated with hypertension and hypertension-related diseases. Thus, it may have the potential to predict the blood pressure response of patients with hypertension to angiotensin-converting enzyme inhibitors (ACEIs).
  
  
  OBJECTIVE
  To investigate the association between the A/C(1166) polymorphism and the blood pressure response to ACEIs in a hypertensive cohort.
  
  
  METHODS
  After a 2-week, single-blind, placebo run-in period, ACEIs were administered for 6 weeks to 509 hypertensive patients. The polymorphism was determined by PCR followed by restriction enzyme digestion.
  
  
  RESULTS
  The AA genotype, AC genotype, and CC genotype were present in 464 (91.2%), 44 (8.6%), and 1 (0.2%) of patients, respectively. As the frequency of the C allele was quite low (0.05), the genotypes were classified according to the presence or absence of the C allele. After 6 weeks of treatment, the systolic blood pressure reductions in patients with the AA genotype and AC + CC genotype were 14.3 +/- 12.6 and 14.1 +/- 12.2 mmHg, respectively (P = 0.908). The diastolic blood pressure reductions in patients with the AA genotype and AC + CC genotype were 8.6 +/- 7.1 and 8.8 +/- 6.9 mmHg, respectively (P = 0.816). There were no differences in the changes in systolic or diastolic blood pressure after treatment among the two genotype groups.
  
  
  CONCLUSIONS
  The AGT1R A/C(1166) polymorphism does not predict the response to antihypertensive treatment with ACEIs in Chinese hypertensive patients.
authors.affiliation: Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, China.
authors.forename: Huimin
authors.initials: H
authors.lastname: Yu
authors.forename: Shuguang
authors.initials: S
authors.lastname: Lin
authors.forename: Lijun
authors.initials: L
authors.lastname: Jin
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Yu
authors.forename: Jiuchang
authors.initials: J
authors.lastname: Zhong
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Zhang
authors.forename: Guozhang
authors.initials: G
authors.lastname: Liu
mesh_terms: D000241:Adenosine / Q000235:genetics*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015331:Cohort Studies; D003596:Cytosine / Q000737:chemistry*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010919:Placebos; D011110:Polymorphism, Genetic; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics*; D016037:Single-Blind Method
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D010919:Placebos; D044140:Receptor, Angiotensin, Type 1; D003596:Cytosine; D000241:Adenosine